Release Date: December 22, 2025
CME Track Expiration Date: December 22, 2026
Pharmacist Track Expiration Date: March 31, 2027
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in the recognition, prevention, and management of oncologic emergencies associated with high-dose methotrexate (HDMTX) treatment. In this educational program, these experts discuss the latest updates in the management of HDMTX, practical strategies for delayed clearance, and toxicity management .
This educational activity is an archive of the live symposium held on December 17, 2025.
Target Audience
This educational activity is directed toward oncologists, hematologists, pharmacists, advanced practice providers (nurse practitioners and physician assistants), and other health care professionals involved in the care of patients receiving high-dose methotrexate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine supportive care requirements for patients with cancer receiving treatment with high-dose methotrexate (HDMTX)
- Integrate online clinical support tools such as mtxpk.org to aid identification of delayed methotrexate clearance
- Apply guideline-based recommendations to manage oncologic emergencies in patients with delayed methotrexate clearance following HDMTX administration
Shazia Nakhoda, MD
Assistant Professor, Malignant Hematology
Fox Chase Cancer Center
Philadelphia, PA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Astra Zeneca, BeiGene; Grant/Research Funding: Beigene, BTG/SERB, Genentech
Shruti Gupta, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Director of Onconephrology
Brigham and Women’s Hospital and Dana-Farber Cancer Institute
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alexion, ArsenalBio, BTG, MediBeacon, Mersana Therapeutics, Orion Pharma; Grant/Research Funding: AstraZeneca, BTG, Janssen; Executive Role (unpaid): President emeritus and co-founder of American Society of Onconephrology
Anitha Varghese, MSN, APRN, AGPCNP-C
Advanced Practice Provider
MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: SERB Pharmaceuticals
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Physicians' Education Resource®, LLC, has approved this application-based activity for 1.00 ACPE CE hours UAN # 0661-0000-25-028-H05-P. Eligibility for credits requires full engagement with the enduring activity, completion and submission of the learner NABP ID # and month and day of birth, activity pre/post-session questions, and the post activity evaluation. This UAN # expires 3/31/2027.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from SERB Pharmaceuticals.